NAMS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
NewAmsterdam Pharma (NAMS) is not a strong buy at the moment for a beginner investor with a long-term focus. While the stock has potential positive catalysts in the mid-term, such as the PREVAIL trial updates and analyst confidence, the lack of recent trading signals, insider selling, and weak financial performance make it prudent to hold off on investing right now.
The technical indicators are mixed. While the MACD is positive and moving averages are bullish (SMA_5 > SMA_20 > SMA_200), the RSI is neutral at 43.926, and the stock is trading below the pivot level of 34.205. Key support is at 32.249, which is close to the current pre-market price of 33.25.
Upcoming updates on the PREVAIL cardiovascular outcomes trial and a potential 2027 launch of obicetrapib could act as major catalysts.
Insiders are selling shares, with a 113.69% increase in selling activity over the last month. The company's financial performance is weak, with a significant YoY revenue decline (-98.80%) and negative net income (-$72M). Additionally, there is no recent news or congress trading data to suggest strong external interest.
In Q3 2025, revenue dropped significantly (-98.80% YoY), net income improved but remains negative (-$72M), and EPS increased to -0.61 (up 238.89% YoY). Gross margin remains at 100%, but the overall financials indicate a struggling company.
Analysts are optimistic, with recent buy ratings and raised price targets. Truist initiated coverage with a $57 price target, Guggenheim raised its target to $45, and RBC Capital increased its target to $47. Analysts highlight confidence in the PREVAIL trial and potential near-term inflection points.
